Clinical Impact of the COVID‐19 Pandemic in Mexican Patients with Thoracic Malignancies

Abstract Background Accumulated evidence indicates that patients with lung cancer are a vulnerable population throughout the pandemic. Limited information is available in Latin America regarding the impact of the pandemic on medical care. The goal of this study was to describe the clinical and social effect of COVID‐19 on patients with thoracic cancer and to ascertain outcomes in those with a confirmed diagnosis. Materials and Methods This cohort study included patients with thoracic neoplasms within a single institution between March 1, 2020, and February 28, 2021. All variables of interest were extracted from electronic medical records. During this period, the Depression Anxiety and Stress Scale 21 (DASS‐2) was applied to evaluate and identify more common psychological disorders. Results The mean age for the total cohort (n = 548) was 61.5 ± 12.9 years; non‐small cell lung cancer was the most frequent neoplasm (86.9%), advanced stages predominated (80%), and most patients were under active therapy (82.8%). Any change in treatment was reported in 23.9% of patients, of which 78.6% were due to the COVID‐19 pandemic. Treatment delays (≥7 days) were the most frequent modifications in 41.9% of cases, followed by treatment suspension at 37.4%. Patients without treatment changes had a more prolonged progression‐free survival and overall survival (hazard ratio [HR] 0.21, p < .001 and HR 0.28, p < .001, respectively). The mean DASS‐21 score was 10.45 in 144 evaluated patients, with women being more affected than men (11.41 vs. 9.08, p < .001). Anxiety was reported in 30.5% of cases, followed by depression and distress in equal proportions (18%). Depressed and stressed patients had higher odds of experiencing delays in treatment than patients without depression (odds ratio [OR] 4.5, 95% confidence interval [CI] 1.53–13.23, p = .006 and OR 3.18, 95% CI 1.2–10.06, p = .006, respectively). Conclusion Treatment adjustments in patients with thoracic malignancies often occurred to avoid COVID‐19 contagion with detrimental effects on survival. Psychological disorders could have a role in adherence to the original treatment regimen. Implications for Practice The pandemic has placed an enormous strain on health care systems globally. Patients with thoracic cancers represent a vulnerable population, with increased morbidity and mortality rates. In Mexico, treatment modifications were common during the pandemic, and those who experienced delays had worse survival outcomes. Most treatment modifications were related to a patient decision rather than a lockdown of health care facilities in which mental health impairment plays an essential role. Moreover, the high case fatality rate highlights the importance of improving medical care access. Likewise, to develop strategies facing future threats that may compromise health care systems in non‐developed countries.

[1]  S. Vergès,et al.  Effectiveness of pulmonary rehabilitation in COVID-19 respiratory failure patients post-ICU , 2021, Respiratory Physiology & Neurobiology.

[2]  D. Pachito,et al.  Delays and Disruptions in Cancer Health Care Due to COVID-19 Pandemic: Systematic Review , 2021, JCO global oncology.

[3]  Maarten J. IJzerman,et al.  Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians , 2020, ESMO Open.

[4]  W. King,et al.  Mortality due to cancer treatment delay: systematic review and meta-analysis , 2020, BMJ.

[5]  R. Dess,et al.  Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic. , 2020, JAMA oncology.

[6]  Davide Algeri,et al.  The Psychological and Social Impact of Covid-19: New Perspectives of Well-Being , 2020, Frontiers in Psychology.

[7]  G. Curigliano,et al.  Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies , 2020, European Journal of Cancer.

[8]  B. Satiani,et al.  The financial and employment effects of coronavirus disease 2019 on physicians in the United States , 2020, Journal of Vascular Surgery.

[9]  G. Curigliano,et al.  Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study , 2020, JCO global oncology.

[10]  M. Rugge,et al.  SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer , 2020, Nature Cancer.

[11]  P. Jänne,et al.  Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus , 2020, Annals of Oncology.

[12]  A. Purushotham,et al.  The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study , 2020, The Lancet Oncology.

[13]  M. Burotto,et al.  Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID‐19 pandemic: the THOCOoP cooperative group , 2020, Critical Reviews in Oncology/Hematology.

[14]  A. Drilon,et al.  COVID-19 in patients with lung cancer , 2020, Annals of Oncology.

[15]  V. Torri,et al.  COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study , 2020, The Lancet Oncology.

[16]  W. Niu,et al.  Cancer associates with risk and severe events of COVID‐19: A systematic review and meta‐analysis , 2020, International journal of cancer.

[17]  M. Santillana,et al.  Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.

[18]  Bram van Ginneken,et al.  CO-RADS – A categorical CT assessment scheme for patients with suspected COVID-19: definition and evaluation , 2020, Radiology.

[19]  H. Miyashita,et al.  Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City , 2020, Annals of Oncology.

[20]  A. Garden,et al.  Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement , 2020, International Journal of Radiation Oncology*Biology*Physics.

[21]  T. Mitsudomi,et al.  Testing for COVID-19 in lung cancer patients , 2020, Annals of Oncology.

[22]  Harapan Harapan,et al.  Coronavirus disease 2019 (COVID-19): A literature review , 2020, Journal of Infection and Public Health.

[23]  C. Vardavas,et al.  COVID-19 and smoking: A systematic review of the evidence , 2020, Tobacco induced diseases.

[24]  T. Lupia,et al.  2019 novel coronavirus (2019-nCoV) outbreak: A new challenge , 2020, Journal of Global Antimicrobial Resistance.

[25]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[26]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[27]  D. Carbone,et al.  Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms. , 2019, Lung cancer.

[28]  L. Lara,et al.  Assessment of the Hospital Anxiety and Depression Scale for cancer patients. , 2018, Revista medica de Chile.

[29]  L. Oñate-Ocaña,et al.  Association of Depression and Anxiety on Quality of Life, Treatment Adherence, and Prognosis in Patients with Advanced Non-small Cell Lung Cancer , 2013, Annals of Surgical Oncology.

[30]  A. Gloster,et al.  Psychometric properties of the Depression Anxiety and Stress Scale-21 in older primary care patients. , 2008, Journal of affective disorders.

[31]  R. Andrés,et al.  Psychometric properties of the Spanish version of Depression, Anxiety and Stress Scales (DASS) , 2005 .

[32]  M. Stanley,et al.  The Depression Anxiety Stress Scale-21: Spanish Translation and Validation with a Hispanic Sample , 2002 .

[33]  P. Lovibond,et al.  The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. , 1995, Behaviour research and therapy.